The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.
 
Katherine Cynthia Fuh
Honoraria - aravive
Consulting or Advisory Role - Aravive; Myriad Genetics
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - AVB-S6-500
 
Michael A. Bookman
Employment - The Permanente Medical Group
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca; Genentech/Roche; Immunogen; Merck Sharp & Dohme; Seagen
 
Robert L. Coleman
No Relationships to Disclose
 
Thomas J Herzog
No Relationships to Disclose
 
Premal H. Thaker
Stock and Other Ownership Interests - Celsion
Consulting or Advisory Role - Aravive; Celsion; Iovance Biotherapeutics; Novocure; Stryker; Tesaro
Speakers' Bureau - AstraZeneca; Merck; Tesaro
Research Funding - GlaxoSmithKline (Inst); Merck (Inst)
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; Mersana; Regeneron; Tesaro
Research Funding - 2X Oncology (Inst); Acetylon Pharmaceuticals (Inst); Agenus (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Regeneron (Inst); Surface Oncology (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck
(OPTIONAL) Uncompensated Relationships - Merck
 
Michelle W. Lane
Employment - Aravive; PRA Health Sciences
Consulting or Advisory Role - Aravive
 
Reshma A. Rangwala
Employment - Aravive
Leadership - Aravive
Patents, Royalties, Other Intellectual Property - Genmab
 
Gail McIntyre
Employment - Aravive
Leadership - Aravive
Stock and Other Ownership Interests - Aravive
Patents, Royalties, Other Intellectual Property - Aravive
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; ChemoID; Clovis Oncology; Deciphera; Eisai; Elevar Therapeutics; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Iovance Biotherapeutics; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Starton Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics
Consulting or Advisory Role - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; ChemoCare; Chemocare; ChemoID; Clovis Oncology; Deciphera; Eisai; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Sorrento Therapeutics; Sorrento Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Kathleen N. Moore
Honoraria - Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Eisai; Genentech/Roche; Immunogen; Merck; Mersana (Inst); Myriad Genetics; Pfizer/EMD Serono; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)